tidbits header CLL Global logo .

Bits and Pieces from the CLL Global Community   




More About Us


Tidbits Archives





 Join our Cause 



Find us on Facebook



If you have recently been diagnosed with CLL, you probably have questions. 


Information about CLL


What we are doing to defeat CLL


List of CLL specialists around the world

(Provided by ACOR) 



How Are SLL and CLL Different?
How Are SLL and CLL Different?

John Pagel, MD, PhD

Fred Hutchinson Cancer Research Center


Does Taking one CLL Treatment Limit Future Options?
Does Taking one CLL Treatment Limit Future Options?

David Maloney, MD, PhD

Fred Hutchinson Cancer Research Center


Working with Your Doctor to Choose a CLL Treatment Path
Working with Your Doctor to Choose a CLL Treatment Path


David Maloney, MD, PhD

Fred Hutchinson Cancer Research Center


Is there something specific you want to read and learn about? 


Let us know if you have any comments or suggestions for improvement.


You are the reason CLL Global exists, and we want to hear from you.




donate button  



September 2014 



As September draws to a close, we hope you had an opportunity to recognize and promote blood cancer awareness month. If not, don't worry. Blood cancer and CLL awareness is a year long effort.


Duvelisib+Obinutuzumab Study Coming Soon


Two combination studies of duvelisib and obinutuzumab will likely be open before the end of 2014, according to Infinity Pharmaceuticals. Duvelisib, also known as IPI-145 is an oral inhibitor of phosphoinositide-3-kinase (PI3K) delta and gamma. Obinutuzumab, also known as Gazyva, is an anti-CD20 monoclonal antibody. Recently approved, Gazyva may be prove to be superior to other anti-CD20 therapies such as rituximab.


In early September, Infinity which makes duvelisib entered into a master clinical supply agreement with Roche which makes Clinical Trial Experiment of a New Product Gazyva. Roche will supply Gazyva for two combination studies. The first will evaulate duvelisib in combination with Gazyva or rituximab in previously untreated indolent non-Hodgkin lymphoma (NHL). The second study will combine duvelisib and Gazyva in patients with CLL whose disease has progressed following treatment with a Bruton's tyrosine kinase (BTK) inhibitor such as ibrutinib. 


As part of the agreement with Roche, Infinity will also supply duvelisib to Roche for scientific research to evaulate the therapeutic potential of the combination. 


Infinity was busy this month. The company also launched a collaboration with Abbvie to further develop and commercialize duvelisib. Abbvie will make an initial payment of $275 mil. to Infinity, and the deal provides for up to $530 mil. in additional milestone payments. 


Ongoing studies with duvelisib include a Phase III monotherapy study in patients with relapsed/refractory CLL and a front-line monotherapy study. In the relapsed/refractory study, named DUO, 300 patients are being randomized to duvelisib or ofatumumab. Prviously presented data indicates an 89% (24/27) nodal response rate.  



Blood Cancer Awareness: September & Beyond


Each September, the blood cancer community works to improve public understanding of the causes of and treatment options for blood cancers. Another goal is to ensure federal funding for blood cancer research.  


In 2010, the US Congress designated September as National Blood Cancer Awareness Month. CLL Global Research Foundation supports the efforts of many individuals and organizations working to raise overall awareness of blood cancers. Unfortunately, too many people do not know about CLL until they or a loved one are diagnosed. Please join us in educating others about CLL and blood cancers in general. Here are a few ways to help all year round:


Educate: Learn more about CLL and then help educate others. Visit www.cllglobal.org for disease-specific information


Share your story: Whether you use Facebook, Twitter, Instagram or other social media, let your friends and neighbors know that blood cancers/CLL are important to you. Or simply post to or like the CLL Global Facebook page.


Donate: Consider making a donation to CLL Global to increase our research efforts.


Participate: Look for events in your area that are enhancing blood cancer awareness. Consider writing your local leaders to proclaim September as Blood Cancer Awareness Month and to proclaim a specific day as CLL day. Start now so CLL can be recognized in 2015.

We look forward to helping raise awareness of CLL throughout September and each day of the year. 


Thanks for joining us for another issue of Tidbits. Stay tuned for more to come.


CLL Global Research Foundation